Sharemaestro Newsreel

Fulcrum (NASDAQ: FULC) plans special cash payout in Slate merger

Fulcrum Therapeutics (NASDAQ: FULC) and Slate Medicines have announced an all-stock merger to create a combined company focused on migraine therapeutics, to be renamed Slate Medicines, Inc. and trade under the symbol SLTE. The merger includes a $245 million private placement for Slate, and …

Fulcrum Therapeutics to Merge With Slate Medicines in Stock Deal Backed by $245 Million Financing

Fulcrum Therapeutics has announced a stock-for-stock merger with Slate Medicines, supported by a $245 million private placement. Upon closing, current Slate holders will own a majority stake, while Fulcrum plans a significant cash dividend to its stockholders, a reverse stock split, and a name …

Veru (VERU) Q3 2026 Earnings Call Transcript

Vivani Medical posts slide presentation under Reg FD; Exhibit 99.1 attached

Vivani Medical has filed an 8-K report, attaching a slide presentation as Exhibit 99.1. This presentation was distributed to the investment community and at conferences, providing key information about the company. The company notes that the presentation reflects information only as of the filing …

Guggenheim raises Celcuity stock price target on drug pricing data

Guggenheim raised its price target on Celcuity Inc (NASDAQ:CELC) to $175 from $165, maintaining a Buy rating, citing the higher-than-expected disclosed price of Revtorpyk. Celcuity plans to begin commercial shipments of Revtorpyk in late Q3 and submit a supplemental new drug application for PIK3CAm …

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Radiopharm Theranostics announced an End-of-Phase 2 meeting with the U.S. FDA on October 1, 2026, to align on the design of a pivotal Phase 3 trial for RAD101. This imaging agent diagnoses recurrent brain metastases and showed 93% concordance with MRI in its Phase …

Radiopharm schedules FDA meeting for brain imaging agent RAD101 By Investing.com

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 trial design for its brain imaging agent, RAD101. RAD101, which has FDA Fast Track Designation, is developed to distinguish recurrent brain metastases from treatment …

EYPT Looks 4000.0% Overvalued on GF Value™

EyePoint Pharmaceuticals (EYPT) is considered 4000.0% overvalued based on GuruFocus's GF Value™ metric, trading at $14.76 against an estimated fair value of $0.36. This extreme valuation comes despite its Duravyu wet AMD trial showing mixed results—failing the primary endpoint in the overall dataset but …

Wedbush initiates Immunic stock with Outperform rating

Wedbush initiated coverage on Immunic Inc. (NASDAQ:IMUX) with an Outperform rating and a $45.00 price target, noting the stock's strong momentum and year-to-date return of approximately 201%. The biopharmaceutical company is developing immune modulators, with its lead program, vidofludimus calcium (IMU-838), in Phase 3 …

OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook

OmniAb Inc. (OABI) saw its stock jump by 21.6% after reporting a strong Q2, beating EPS estimates by $0.08 and nearly tripling revenue expectations. The company also raised its 2026 revenue guidance to $32M–$36M and completed discovery work on a key collaboration, positioning it …

OmniAb Inc. Stock Pops As Earnings Beat Fuels Guidance Hike

OmniAb Inc. (NASDAQ: OABI) saw its stock price surge by 21.6% after reporting a strong Q2 earnings beat, exceeding EPS estimates by $0.08 and nearly tripling revenue expectations. The company also raised its 2026 revenue guidance to $32M–$36M, up from previous estimates, and announced …

Alpha Cognition (ACOG) Stock Fair Value Rises After Zunveyl Analyst Optimism

Alpha Cognition's (ACOG) fair value price target has increased from US$14.67 to US$16.75, attributed to analyst optimism surrounding its drug Zunveyl. Analysts highlight strong Q2 results, improving commercial execution, positive payer discussions, and Zunveyl's potential to address tolerability issues in Alzheimer's treatment. While bullish …

Moderna stock steadies after FDA clears first mRNA flu shot for older adults

Moderna's stock is stabilizing in the low-$60s after the FDA approved its first mRNA flu vaccine for adults over 50, a significant milestone for the company. This approval opens a new market segment and helps Moderna diversify beyond its COVID-19 franchise, despite the stock's …

SRRK: Scholar Rock's Moment Of Truth FDA, Cash, & Catalysts Demaryius Thomas (Ve0ekHXG4S)

CVKD Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline - Downward Estimate Revision

Alpha Cognition (ACOG) Gains 2.43% to $8.84, Approaching Key Resistance at $9.28 - Value Factor

Capricor Therapeutics (CAPR) Could Be 89% Undervalued Following Deramiocel And Loss Concerns

Capricor Therapeutics (CAPR) is under scrutiny after reporting wider Q2 2026 losses and ongoing legal/regulatory questions regarding its Duchenne muscular dystrophy candidate, Deramiocel. Despite recent share price volatility, with jumps of 58% in one day and 73% in seven days, the stock is still …

Eupraxia Pharmaceuticals (EPRX) Edges Higher to $6.72 as Biotech Sector Holds Steady - Equal Weight ETF

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00

HC Wainwright has increased its price target for ArriVent BioPharma (NASDAQ:AVBP) to $47.00 from $44.00, maintaining a "buy" rating and implying a 59% upside. This comes amidst a generally positive analyst sentiment, with eight analysts rating the stock a "Buy," one a "Hold," and …

Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT

Monaco Asset Management SAM has acquired a new stake worth $8.48 million in Rocket Pharmaceuticals (NASDAQ: RCKT), making it the firm's 11th largest holding and representing 2.27% of the biotechnology company's shares. Despite institutional investors owning 98.39% of the stock and the company beating …

H.C. Wainwright reiterates ProQR stock rating on platform data

H.C. Wainwright has reiterated its Buy rating and $12.00 price target for ProQR Therapeutics (NASDAQ:PRQR), citing strong platform data, particularly for AX-0810, which showed promising target engagement and an eight-week half-life in a Phase 1 study. The firm believes AX-0810's differentiated mechanism could address …

A PET scan matched MRI in 93% of lesions—what comes next?

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. The company's Phase 2b trial showed a 93% concordance between MRI …

NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand

NRX Pharmaceuticals reported a net loss of $18.0 million for the first half of 2026, with an operating loss widening to $11.3 million. The company holds $26.7 million in cash and expects current resources, revenue growth, and an at-the-market facility to fund operations for …

AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX

AIGH Capital Management LLC has acquired 2,795,797 shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX), valued at approximately $24.9 million, making it their 10th largest holding. Despite Kyverna beating its quarterly EPS estimates, analysts anticipate the clinical-stage biotech will remain unprofitable this year. While HC Wainwright …

CGTX Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.04 Per Share - Earnings Forecast Report

BCDA Q2 2026 Earnings: EPS Surprise of 29.19% Narrows Losses as Shares Climb 4.82% - Estimate Revision Count

Arcus Biosciences (RCUS) Advances 2.15% as Oncology Pipeline Momentum Builds - EMA Signal

Cocrystal Pharma, Inc. Announces Appointment of Carol Brosgart, Md to Board of Directors, Effective August 12, 2026

Cocrystal Pharma, Inc. announced the appointment of Dr. Carol Brosgart to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings decades of experience in antiviral therapy, epidemiology, and biopharma advisory, including a critical role in the development of antiviral therapies at Gilead …

Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN

Persistent Asset Partners Ltd has made a new investment of $4.57 million in BioMarin Pharmaceutical Inc., acquiring 79,933 shares, which now constitutes 1.4% of its portfolio. BioMarin recently reported strong Q2 earnings, surpassing analyst estimates with $1.20 EPS and $989.71 million in revenue, and …

Monaco Asset Management SAM Invests $10.58 Million in BioMarin Pharmaceutical Inc. $BMRN

Monaco Asset Management SAM has invested $10.58 million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), acquiring 184,937 shares, making it their eighth-largest holding. This investment comes as BioMarin reported strong quarterly earnings, beating analyst estimates with $1.20 EPS and a 20% revenue increase year-over-year. Analysts generally …

Weekly Recap: CAN-2409 BLA filing, 2027 U.S. launch target and Q2 widened loss, shares up

Candel Therapeutics (CADL) is preparing to file a Biologics License Application (BLA) for CAN-2409 in Q4 2026 for localized prostate cancer, aiming for a 2027 U.S. launch. The company reported a wider Q2 adjusted loss and no revenue, but its shares have increased significantly …

H.C. Wainwright reiterates Celcuity stock rating on pricing update

H.C. Wainwright has reiterated its Buy rating and $155 price target for Celcuity Inc (NASDAQ:CELC) following the company's Q2 results and corporate update, despite the stock being considered overvalued by InvestingPro data. Analysts maintain a Strong Buy consensus, with price targets ranging from $140 …

UBS raises Acadia Pharmaceuticals stock price target on trial optimism

UBS has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $49 from $45, maintaining a Buy rating, due to increased optimism for its drug remlifanserin in Alzheimer’s disease psychosis. The firm raised its probability of success for remlifanserin to 50% and its …

Wainwright reiterates Dyne Therapeutics stock rating on trial outlook

H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Dyne Therapeutics (NASDAQ:DYN), citing the upcoming HARBOR trial data readout as a significant catalyst for DM1 treatment. The firm anticipates the HARBOR trial will meet its primary endpoint, drawing comparisons to …

Raymond James raises Praxis Precision Medicines price target on pipeline outlook

Raymond James has increased its price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX) shares from $765 to $945, maintaining a Strong Buy rating. This upgrade is driven by an increased probability of success for the company's EMERALD trial and higher peak sales forecasts for …

H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target

H.C. Wainwright has reiterated a Neutral rating and $25.00 price target for Alumis Inc (NASDAQ:ALMS), emphasizing upcoming clinical trial results for Sjögren’s disease and systemic lupus erythematosus as critical for the stock's future, potentially opening a second therapeutic path beyond psoriasis. The firm highlights …